BioNexus Gene Lab (BGLC) EPS (Weighted Average and Diluted) (2023 - 2025)
Historic EPS (Weighted Average and Diluted) for BioNexus Gene Lab (BGLC) over the last 3 years, with Q3 2025 value amounting to -$0.4.
- BioNexus Gene Lab's EPS (Weighted Average and Diluted) rose 4726.3% to -$0.4 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.16, marking a year-over-year increase of 6820.44%. This contributed to the annual value of -$0.09 for FY2024, which is 4583.39% up from last year.
- As of Q3 2025, BioNexus Gene Lab's EPS (Weighted Average and Diluted) stood at -$0.4, which was up 4726.3% from -$0.34 recorded in Q2 2025.
- Over the past 5 years, BioNexus Gene Lab's EPS (Weighted Average and Diluted) peaked at $0.11 during Q2 2024, and registered a low of -$0.75 during Q3 2024.
- In the last 3 years, BioNexus Gene Lab's EPS (Weighted Average and Diluted) had a median value of -$0.03 in 2024 and averaged -$0.18.
- Over the last 5 years, BioNexus Gene Lab's EPS (Weighted Average and Diluted) had its largest YoY gain of 4726.3% in 2025, and its largest YoY loss of 48333.33% in 2025.
- Quarter analysis of 3 years shows BioNexus Gene Lab's EPS (Weighted Average and Diluted) stood at $0.02 in 2023, then plummeted by 188.29% to -$0.02 in 2024, then plummeted by 1920.65% to -$0.4 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.4 in Q3 2025, compared to -$0.34 in Q2 2025 and -$0.04 in Q1 2025.